Beam Therapeutics (BEAM) is back in focus after highlighting plans to present updated biomarker data from its BEACON Phase 1/2 risto-cel trial in sickle cell disease at the European Hematology Association 2026 Congress.

Despite the recent earnings update and upcoming clinical data presentations, Beam Therapeutics’ short term share price momentum has cooled, with the 7 day share price return down 13.58%, although the 1 year total shareholder return of 56.12% still points to stronger longer term performance.

If this kind of clinical news has your attention, it can be a good moment to look across the sector and see what else is moving with 32 healthcare AI stocks

With Beam’s stock up 56.12% over the past year but still trading well below the average analyst price target of US$51.07, investors now face a key question: Is there still upside here, or is future growth already priced in?

Most Popular Narrative: 81.4% Undervalued

Beam Therapeutics last closed at $27.93, compared with a narrative fair value of $150 according to a detailed risk adjusted valuation shared by the community.

The provided deep-dive research utilizes a Risk-Adjusted Net Present Value (rNPV) model rather than a traditional DCF, as it is more appropriate for a pre-revenue clinical-stage company.

This sum-of-the-parts rNPV analysis of only the two lead assets (BEAM-101 and BEAM-302) derives a base-case intrinsic value of $65 per share.

Curious how a pre revenue biotech gets to a much higher fair value than today’s price? The narrative leans heavily on ambitious revenue build up, carefully chosen success probabilities, and a cash position that supports those assumptions without factoring in every program in the pipeline.

Result: Fair Value of $150 (UNDERVALUED)

However, this bullish setup still depends on clinical readouts and regulatory decisions landing as hoped. Any safety issues or delays are likely to challenge the upside case.

Next Steps

With the story so tilted toward potential upside but carrying real clinical and execution risks, it makes sense to move quickly and test the thesis against the data yourself. Start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your goals even better, so use the data to widen your watchlist intelligently.

• Target potential mispricing by scanning a curated set of 51 high quality undervalued stocks that combine attractive valuations with solid underlying metrics.
• Strengthen stability in your portfolio by reviewing companies from the solid balance sheet and fundamentals stocks screener (45 results) that score well on debt and liquidity measures.
• Spot underfollowed opportunities early by checking the screener containing 21 high quality undiscovered gems that pair quality fundamentals with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.